TY - JOUR
T1 - Proof of concept of a personalized genetic risk tool to promote smoking cessation
T2 - High acceptability and reduced cigarette smoking
AU - Ramsey, Alex T.
AU - Bourdon, Jessica L.
AU - Bray, Michael
AU - Dorsey, Amelia
AU - Zalik, Maia
AU - Pietka, Amanda
AU - Salyer, Patricia
AU - Chen, Li Shiun
AU - Baker, Timothy B.
AU - Munafò, Marcus R.
AU - Bierut, Laura J.
N1 - Funding Information:
We wish to acknowledge Dr. Erika Waters of the Department of Surgery, Washington University School of Medicine (St. Louis, MO) for her feedback on this article. We also thank the study participants for providing and sharing their genetic data with the study team to inform the personalized intervention. A.T. Ramsey was supported by the National Institute on Drug Abuse (NIDA) grant K12DA041449 and the NCI grant P50CA244431. J.L. Bourdon was supported by NIDA grant T32DA015035. L-S. Chen was supported by the NCI grant P30CA091842-16S2 and NIDA grant R01DA038076. L.J. Bierut was supported by NIDA grant R01DA036583, National Center for Advancing Translational Sciences grant UL1TR002345, and NCI grant P30CA091842.
Funding Information:
A.T. Ramsey reports grants from NIH/National Institute on Drug Abuse and NIH/NCI during the conduct of the study. J.L. Bourdon reports supported by NIDA T32DA015035 to complete this work. L.J. Bierut reports a patent for U.S. Patent 8,080,371 (markers for addiction, licensed to L.J. Bierut). No disclosures were reported by the other authors.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Relatively little is known about the possible effects of personalized genetic risk information on smoking, the leading preventable cause of morbidity and mortality. We examined the acceptability and potential behavior change associated with a personalized genetically informed risk tool (RiskProfile) among current smokers. Current smokers (n = 108) were enrolled in a pre-post study with three visits. At visit 1, participants completed a baseline assessment and genetic testing via 23andMe. Participants' raw genetic data (CHRNA5 variants) and smoking heaviness were used to create a tailored RiskProfile tool that communicated personalized risks of smoking-related diseases and evidence-based recommendations to promote cessation. Participants received their personalized RiskProfile intervention at visit 2, approximately 6 weeks later. Visit 3 involved a telephone-based follow-up assessment 30 days after intervention. Of enrolled participants, 83% were retained across the three visits. Immediately following intervention, acceptability of RiskProfile was high (M=4.4; SD=0.6 on scale of 1 to 5); at 30-day follow-up, 89% of participants demonstrated accurate recall of key intervention messages. In the full analysis set of this single-arm trial, cigarettes smoked per day decreased from intervention to 30- day follow-up [11.3 vs. 9.8; difference = 1.5; 95% confidence interval (0.6-2.4); P = 0.001]. A personalized genetically informed risk tool was found to be highly acceptable and associated with a reduction in smoking, although the absence of a control group must be addressed in future research. This study demonstrates proof of concept for translating key basic science findings into a genetically informed risk tool that was used to promote progress toward smoking cessation. Prevention Relevance: This study demonstrates that personal genetic information can be incorporated into a risk feedback tool that was highly acceptable to current smokers and associated with reductions in smoking. These findings may pave the way for effectiveness and implementation research on genetically-informed behavior change interventions to enhance cancer prevention efforts.
AB - Relatively little is known about the possible effects of personalized genetic risk information on smoking, the leading preventable cause of morbidity and mortality. We examined the acceptability and potential behavior change associated with a personalized genetically informed risk tool (RiskProfile) among current smokers. Current smokers (n = 108) were enrolled in a pre-post study with three visits. At visit 1, participants completed a baseline assessment and genetic testing via 23andMe. Participants' raw genetic data (CHRNA5 variants) and smoking heaviness were used to create a tailored RiskProfile tool that communicated personalized risks of smoking-related diseases and evidence-based recommendations to promote cessation. Participants received their personalized RiskProfile intervention at visit 2, approximately 6 weeks later. Visit 3 involved a telephone-based follow-up assessment 30 days after intervention. Of enrolled participants, 83% were retained across the three visits. Immediately following intervention, acceptability of RiskProfile was high (M=4.4; SD=0.6 on scale of 1 to 5); at 30-day follow-up, 89% of participants demonstrated accurate recall of key intervention messages. In the full analysis set of this single-arm trial, cigarettes smoked per day decreased from intervention to 30- day follow-up [11.3 vs. 9.8; difference = 1.5; 95% confidence interval (0.6-2.4); P = 0.001]. A personalized genetically informed risk tool was found to be highly acceptable and associated with a reduction in smoking, although the absence of a control group must be addressed in future research. This study demonstrates proof of concept for translating key basic science findings into a genetically informed risk tool that was used to promote progress toward smoking cessation. Prevention Relevance: This study demonstrates that personal genetic information can be incorporated into a risk feedback tool that was highly acceptable to current smokers and associated with reductions in smoking. These findings may pave the way for effectiveness and implementation research on genetically-informed behavior change interventions to enhance cancer prevention efforts.
UR - http://www.scopus.com/inward/record.url?scp=85100582318&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-20-0328
DO - 10.1158/1940-6207.CAPR-20-0328
M3 - Article
C2 - 32958583
AN - SCOPUS:85100582318
VL - 14
SP - 253
EP - 262
JO - Cancer Prevention Research
JF - Cancer Prevention Research
SN - 1940-6207
IS - 2
ER -